The American multinational Johnson & Johnson obtained a net profit of 4.556 million euros in the third quarter, representing an increase of 21,6% compared to the same period last year.
Between July and September, sales totaled €24.313 billion, up 1,9% from the same quarter of 2021. “ Our performance during the third quarter of the year demonstrates continued strength and resilience across all three business lines ,” stated Johnson & Johnson CEO Joaquin Duato.
Growth in all areas of business.
All of the company's business areas increased their sales. The Consumer and Healthcare divisions grew 4,8% globally during this third quarter, driven primarily by the Aveeno and Neutrogena brands.
On the other hand, the Pharmacy division improved by 9,2% as a result, among other factors, of the positive reception of the Covid-19 vaccine marketed under the Janssen brand. Finally, global sales of medical devices increased by 8,1%.
future
In the first nine months of the year, Johnson & Johnson's net profit was €14.737 million, down 10,7% from the previous year. At the same time, sales totaled €72.799 million, up 3,3% from 2021.
For the year as a whole, forecasts point to revenues between €95.039 and €95.550 million. “ Thanks to the efforts of our teams around the world, we will continue to navigate the dynamic macroeconomic environment and remain focused on providing innovative healthcare solutions ,” says Joaquin Duato, who acknowledges that he remains confident in the business and its ability to continue advancing the brand portfolio.
